Fire breaks out at Hyderabad-based Aurobindo Pharma’s plant

New Delhi:  Aurobindo Pharma on Monday said a fire incident occurred at the Andhra Pradesh-based plant of its subsidiary Lyfius Pharma on April 27, leading to temporary suspension of operations.

The incident resulted in damage to certain ancillary equipment with no impact on the core manufacturing infrastructure at the Penicillin-G production facility located in Kakinada, the Hyderabad-based drug maker said in a regulatory filing.

Importantly, there were no injuries reported, it added. “As a precautionary measure and to facilitate necessary equipment replacements, operations at the plant will be temporarily paused for an estimated period of 20 to 25 days,” the company said.

A thorough assessment of the damage is currently underway, it added. “We remain committed to resuming full operations at the earliest,” Aurobindo Pharma said.

Related Posts

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. Zydus Lifesciences reported a rise in…

Chemists strike on May 20: Reasons behind today’s all-India strike

While major pharmacy chains and government medical outlets will remain operational, the strike highlights significant tensions within the industry that could impact access to medications nationwide. The All India Organisation…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug

GSK’s Calpol a well-known trademark: High Court

GSK’s Calpol a well-known trademark: High Court

3 arrested for allegedly posing as doctors using forged MBBS degrees

3 arrested for allegedly posing as doctors using forged MBBS degrees

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures